In short
Podcast Episode Notes: CNBC's "Fast Money"
Episode Title
Intel CEO Stepping Down… And Fast Money’s Obesity Week Kicks Off 12/2/24
Episode Description
- Discussion on Intel CEO Pat Gelsinger stepping down amid challenging years for the company.
- Insights into potential turnaround plans for Intel and competition in the semiconductor industry.
- Introduction to Fast Money’s Obesity Week, focusing on emerging players in the weight-loss drug economy.
---
Key Topics Discussed
- Intel CEO Shakeup
- CEO Transition: Pat Gelsinger was ousted after nearly four years of underperformance, with the company struggling with declining market share and unable to compete effectively in AI.
- Stock Performance: Shares saw a brief rise of 6% following the announcement but ended negatively; Intel was the only stock in the SMH ETF that declined that day.
- Expert Opinions:
- Guy Adami: Critiques Gelsinger's tenure, citing a 60% stock drop and persistent poor performance. Suggests that merely cutting costs won’t lead to success without innovation.
- Tim Seymour: Sees potential for improvement after the leadership change, emphasizing the need for a manufacturing partner like Taiwan Semiconductor (TSMC).
- Market Dynamics for Intel
- Stock Picker's Market: Discussion on the shifting environment where individual company performance is becoming increasingly important compared to the broader market trends.
- Long-Term View: Some analysts, including Tim and Savita Subramanian, believe there may still be opportunities for recovery in 2025, although the current situation is fraught with uncertainty.
- Broader Semiconductor Landscape
- Competitors: Companies like AMD and NVIDIA are outperforming Intel, raising serious questions about Intel's competitive standing moving forward.
- Analyst Insights: Chris Rowland of Susquehanna predicts Intel may need to split its design and manufacturing components to unlock value.
- Obesity Market Insights
- Weight Loss Drugs: Discussion led by former FDA Commissioner Scott Gottlieb on the evolving landscape of weight loss medication, particularly GLP-1 drugs.
- Public Health Implications: Emphasizes the importance of these drugs for patients with high BMI and potential new indications for cardiovascular risk reduction.
- Political Landscape: Speculation on how upcoming political changes could affect drug approval and utilization patterns.
---
Key Takeaways
- Intel's Leadership Change: Seen as a necessary but complicated shift, with analysts optimistic about potential partnerships yet wary of deeper company issues.
- The Weight Loss Drug Market: Ongoing developments may positively impact the public health landscape, but the market's trajectory is contingent upon political factors and regulatory approval.
- Investment Strategies: Focus on stock picking is advised in the current market environment, with an emphasis on potential recovery stories in both semiconductor and health sectors.
---
Final Thoughts
- The podcast episode highlights significant shifts in both the semiconductor industry with Intel's leadership change and the evolving landscape of obesity treatment drugs. Investors and analysts are encouraged to adopt a selective investment approach, focusing on companies poised for recovery amidst broader market fluctuations.
For further details, refer to the full episode on [CNBC's Fast Money](http://fastmoney.cnbc.com).
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:01Live from the Nasdaq market site in the heart of New York City's Times Square this is Fast Here's what's on tap tonight. On the out at Intel, Pat Galsinger ousted from the CEO spot at the semi-company after nearly four years of lackluster results. But will new leadership be able to turn around a long, struggling stock? We'll debate that. Plus, resilient retail consumer stocks have been outperforming the broader market over the past month. Will holiday shoppers keep this trade in rally mode? And we're kicking off Obesity Week here on Fast Money. former FDA Commissioner Scott Gottlieb on set to discuss the latest developments and how the weight loss space could be impacted by the next administration.
0:36I'm Melissa Lee. I'm going to be live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Dan Nathan, Guy Adami, and Savita Subramanian, head of U.S. equity and quantitative strategy at Bank of America Securities. Welcome, Savita. We start off with the Intel CEO shakeup. Pat Gelsinger abruptly pushed out from the top spot after almost four years at the helm. The board announcing that the The company's CFO and products head will take over as interim co-CEOs. The U.S. chipmaker has struggled with declining market share and has failed to gain traction in the AI race. The stock was down more than 60 percent under Gelsinger's tenure.
1:09Today's news initially sent shares popping as much as 6 percent. But the end of the session in the red, it was the only stock in the SMH ETF down today with names like Taiwan Semi, AMAT, Marvell, all seeing outsized gains. And so what does this mean that this news couldn't even get shares of Intel rallying? Seems like there's deeper troubles ahead, Guy. You know, I want to be kind here, but then again, I don't want to be kind. We've not ever been kind to Pat Gelsinger because of the performance. Justify myself. Apparently we played a video. I wasn't paying any attention. I'm sorry, Sandy. I'm sure it was great.
1:42But you think about it. It's almost impossible to have that kind of. There it is. One, two. I mean, that's it. See, and you know what's amazing? Why do it at all? Why do it at all? Why do it at all? Anyway. And that was, I think, the beginning of the end. And so when the stock is down. Actually, the stock was down like 60 % at the point he did that and it went down another 60%. Which is remarkable. And over that same period of time, think about what semiconductors have done and think about what the broader market has done. So it's really difficult to have that kind of underperformance. With that said, you'll read about how Intel is a difficult company to manage.
2:20a lot of moving parts. But, you know, the bottom line is you can't cut your way and then lack of innovation your way to prosperity. And that's what's been going on there. With that said, I'm surprised the stock behaved the way it did today. If you had told me a week ago this would happen, I'd say the stock's going to be up 5%. It wasn't. But I'm still probably one of the few people that think there might be some opportunity here in 2025 for a name like Intel. It was initially. And then the analysts started coming out saying, maybe this raises questions about the path of manufacturing. It raises broader questions about its progress, etc.
2:50balance sheet. Exactly. Exactly. So I think at one point it was up six and a half percent, at least pre-market. And what what signified here is that the board has a search committee. I don't think they knew this was coming. And so you can say that's good news or bad news. I'll take a glass half full just because we we we know change was needed at Intel, abrupt change. And in fact, I think that the path forward here could be one where they find a manufacturing partner. Taiwan Semi has always been that path. Now I realize there's politics around that. But I do think getting in partnership to eventually enable TSMC wafers to work with the Intel fabs is part of at least a story where they're relevant now, even while all the exciting, sexy stuff, I think, is out of the way.
3:33So, yeah, I think you have to like the news. There's no quick fix. You know, it's so interesting. This is one of the biggest years in terms of CEO and C-suite changes that we've seen for the S &P 500. I feel like this is telling us that we're moving into a stock pickers market. because, you know, a year ago, it didn't matter who was at the helm. It was all macro and rate risk. But I think this is a really interesting sign that it's becoming much more idiosyncratic. Yeah, and I think to Tim's point about who benefits from this, I mean, there's going to be a whole heck of a lot of uncertainty for a while.
4:05We talked about this summer, there was a rumor about Qualcomm looking to possibly buy Intel. And the fact that Qualcomm actually commented on it at the time, they said they're not going to consider anything until after the election. And so here you are. I mean, there's probably not a lot of great history seeing a CEO ousted, having a board potentially shaking up and seeing a kind of merger or an acquisition of this sort of size. But I think to Tim's point about who benefits, you know, so Taiwan Semi was up 5 percent. I thought it was kind of curious why AMAT. So they're a provider of machines that obviously make the chips.
4:37That was also up 5 percent, kind of filled in the gap. So there must be some angle there. But, you know, we talk about it all the time. And Sabita just said it's stock pickers market. It's like you don't really want to be buying value stocks in a rip-roaring bull market like this. They just don't work particularly well. At some point, you're starting to see a lot of crap starting to rally as the market is kind of broadening out a little bit. And if this thing can't get out of its own way, it has that huge gap from earnings a couple months ago. And just assume whoever takes over, they're going to do exactly what Gelsinger did in early 2021.
5:06They had a plan? No, no. You're going to clear the decks. You're going to guide down so you can make it. So there's probably more gaps to be had in this one. So let's say we're trying to find the value here. What is the path, in your view? I mean, if they shed manufacturing, if they don't go down that very, very costly plan to go into manufacturing and build all sorts of – I mean, what is left of Intel? Or maybe that is the way to plow forward with that. I think it's to plow forward with that. And I think it's also to say, hey, you know, we've been behind the curve in obviously semiconductors that are the growth area.
5:36We're clearly – they're data businesses. I mean, that clearly has been a drag. But I do think there's opportunity. And if you look at, again, we've mentioned this, it didn't work out. But in terms of Homeland Security plays and the importance of Intel in the United States, I mean, there's an argument to be made. And by the way, there were a lot of old tech companies over the last five or six years that were left for dead. IBM being one, Oracle being another, that seemingly found their way out of nowhere. I think Intel can be one of those companies. Building foundry, as I think I'll say, is costly and it's going to take some time.
6:06So you get the sense that there's some need to have more financial stability in the short term. And that means there's going to be asset sales. There's going to be there are going to be partnerships and there's going to be a lot of government help. So I think the story remains somewhat murky here. And I think really it entails existential existence. You know, is if this was a Jean Paul Sartre class school, you know, we would all be questioning who they think, well, this is what we do once in a while. Anyway, well, the last thing I'll just say is we've heard this again and again over the last month or so.
6:36since earnings season really got going is that the PC business is really bad. You know what I mean? Even the smartphone business is not particularly great. They don't have a lot of exposure there. But the PC stuff, they do. And so to me, if you don't have a chip, and AMD has shown us this, if you don't have something that's competitive with AMD and generative AI, you're kind of nowhere. And if that other business that you're relying on to keep you above the fold is not doing particularly well, there's a breakdown right there. It's not a great place to be. All right. For more, let's bring in Chris Rowland of Susquehanna.
7:05Chris, what's your take? Nick, what is Intel's path forward? Is this a value stock? It's certainly not a growth stock. So I believe that they had some sort of a setback here. It could be guidance for the quarter. It more likely, though, is a setback on their five nodes in four years. That was Pat's plan. And perhaps even 18A, more specifically, their next big node that may have slipped here. And this puts everything kind of into jeopardy. This does not seem like this was something that was planned. It seemed a little bit more sudden. I think Pat was like ride or die Intel. He was ride or die American manufacturing.
7:51And so my guess is that something slipped here. It could have been in the roadmap. And this puts kind of the whole PAP plan in jeopardy. So you mentioned the quarter and could it be because the quarter was bad, the current quarter, I'm assuming. I mean, the August quarter was horrendous. And so for you to say that the current quarter is something went wrong, that means it's horribly wrong, considering in that August quarter, they cut their guidance for the year. They cut their workforce by 15 percent. They suspended the dividend. I mean, you name it, it was terrible news that day. Yeah, it was an awful update.
8:31And like I said, Pat may be leaving because of the December guidance. I do think, however, it's more likely about manufacturing, more likely about that roadmap, and 18A perhaps slipping as well. This was his thing, five nodes, four years. And so if That doesn't work. He doesn't work. Intel's plan of becoming the next manufacturing American giant. That doesn't work either. I think that's more likely it rather than guidance. So, Chris, it's Tim. Thanks. This gets us then to kind of that question we were getting to earlier about the philosophy. But it really gets back to and I think one of your competitors has a statement out there that they need a technologist to solve technology problems.
9:21And I'm curious if that's what you think, too, and really gets back to who are they? What are they going to be here? Yeah, I think the path forward here, back to Melissa's question, is to break the company into two. And it's to break the product or design part of the company away from manufacturing. Manufacturing is going to be low multiple, high value. You're going to have to inject CapEx. Perhaps you can even sell part of the design slash product business to inject capital into the foundry part of this. But the design part of this, and perhaps the part that Qualcomm is interested in here, is quite valuable.
10:06But for some reason, AMD has a$250 billion market cap and Intel only has$100, even though they still have majority share in both servers and PC over AMD. So I do believe that there is value there, but it's being completely masked by this manufacturing business that is something like a relic of a decade or two past. Yeah, the margin deterioration over the last couple of quarters has been dramatic. I mean, this last, Mel just said it was a disaster. I mean, is there anything in the short term they can do to focus on things at a higher margin that might be able to move the needle that might get people excited about the name again?
10:49You know, truthfully, not really. So they have actually moved to TSM and these products, Lunar Lake for PC in particular, are benchmarking really well. And ironically, it's not their own silicon. So that is weighing on gross margin. The thing they're trying to do is bring their own products into their own product, their own manufacturing into their own products to increase gross margin. But that's not expected until late 2025. So there's not a lot that they can do right now. And so, you know, the die has kind of been cast here. Ali Ayakta-Est, the die has been cast. Very nice. Whoa, look at you.
11:35I keep going here. Whoa. All right, Chris. So$24 a share approximately as we're Intel trading now. If you are right and they break up the company, should you be a shareholder right now thinking that value will be unlocked? Or is this just a no touch completely? I don't know. We're going to have to do some deep work on breaking this apart. It really matters how much cash needs to be injected into the manufacturing operations. Are they going to shut down, for example, the Ohio construction that's underway right now? There's a big mud pit. Are they going to shut that down? How much capital do they need?
12:19What are they ultimately going to do with that? But my guess is if they can cleave these off successfully, the two parts are probably worth more than 30 bucks in aggregate. But we need to do some deeper work. And there are some big questions that need to be answered if we were to do that. Chris, great to speak with you. Thank you. Thank you, guys. Chris Rolland of Susquehanna. A lot of hair on this story. Do you want to touch this one? So to Guy's point about margins. I mean, you know, back in 2019, this is a company that did$22 billion in net income. OK, and they had 67 percent gross margins.
12:55They're expected to have 35 percent gross margins this year. And the company swung to a loss. I don't know how you come back for that. It really is a sum of the parts story. They're not going to be able to kind of compete from a technology standpoint with the places that they need to do with this sort of financial performance. So I hate to be so dire about it. I think it does get sold for parts. You're still a shareholder. I am. And, you know, I'm a much smaller shareholder, not just through drawdown. But, you know, I don't it's been very difficult because when you asked about the value dynamic, there's no value in terms of the earnings multiple.
13:26There's no value here at all. I mean, this stock isn't cheap. I think it gets back to a couple of things. I think the board is in a much more independent position. Savita is bringing up a great point about think about the year of 2024 and what it's meant for CEOs getting kicked out of the door. And we're talking about high profile CEOs. Enough is enough. There's a couple also who look like they're about to go. I won't name companies, but they're hanging in there. I think for the semiconductor space, it will get back to stock picking. And I think if you look at the semi space since six months is actually down one and a half percent to the S &P's, you know, whatever it's doing.
13:59It's underperformed retail by 1500 basis points. So, you know, that's a dynamic here. And if you look at AMD relative to NVIDIA, that's a place where I think that that pair looks interesting, even though you don't have that kind of growth. I like MD. You know, I'm just going to give you a quant stat. So divestitures, you kind of want to own them. The statistics show that companies that break up or spin out generally outperform. Over what time period? So we looked at, I think it was like a six-month time frame. So maybe you have to be patient, but it's usually a good idea. Companies don't do it unless they have to.
14:35Yeah, but Hewlett was a bit of a disaster. I mean, like, you know, I think in tech it's a kind of hard thing. Right. guy? Franz Kafka wrote The Metamorphosis. Gregor Sampson? Yes. A literary show. Gregor Sampson is sort of the Pat Gelsinger. If you treat somebody like a bug, they turn into a bug. And I think that's what we're seeing here. So who is the bug in this metaphor? Pat Gelsinger is the bug? He's the Gregor Sampson. He never really busted out of his cocoon. They had him in the basement. They threw an apple. It lodged in his back. With all that said, I mean, I do think if you're looking for a trade in 2025, I think Intel could be one of those ones that surprise people to the upside.
15:17All right. Well, tech spending is one of the big reasons why our guest trader, Savita Subramanian, is bullish on stocks. She's got a 66.66 price target on the S &P 500 for next year, which implies a 10 % gain from today's close. So what do we know about you? You like stock picking here. That's how we'll get there. I like stock picking, but I think even the index, it's hard to say there's more downside risk than upside risk. And here's my call. I know that everybody is bullish and it feels like sentiment has hit these really high levels where you want to sell. But the truth is there is euphoria in one specific pocket of the market, and that is mega cap tech.
15:55Outside of that, there's not a lot of bulls on your average company. The other factor that I think is so interesting is if you look at the spread between the average S &P company and the index itself, massive difference. So, you know, again, I'll say it again, and we all know this, but the index is very top heavy. But the average company in the index is actually trading at relatively healthy multiples. I think, you know, going back to this manufacturing theme, I think this could be the beginnings of a stronger environment for manufacturing. Because when you look at, you know, ground that's been broken around reshoring or building out grid and infrastructure, we're in an environment where this is a long tailed theme.
16:37Most tech companies have told us that the key risk around AI is underinvesting. So they basically told us they're going to spend a lot of money over the next several years on not just tech, but, you know, power, infrastructure, metals, machinery. That huge pickup, I think, in terms of manufacturing dollars spend. As a strategist, do you always believe what companies are going to tell you about what they need to do going forward? And I mean that sincerely, because, again, you have to chronically disbelieve what they're saying. Because the upside to CapEx spends as a percentage basis keeps going lower.
17:14I know the numbers, the absolute numbers are going higher. That's the one thing I would kind of worry about, because if the rest of the sectors that have not been infected or not euphoric, as you just mentioned, don't spend, if they don't see the return on investment, then the CapEx is going to come down pretty quickly. Well, I don't necessarily think so. In fact, I think what we're seeing now is just the beginnings of an acceleration in CapEx. And here's why. The U.S. has underinvested in its own infrastructure for more than 10 years, right? Stuff is old in the U.S. and it's starting to break.
17:45Meanwhile, since 2015, we've moved all this manufacturing capability from other parts of the world to the U.S. And we're starting to see municipalities fray, right? I mean, if you look at the accident rate in certain municipalities, it's really jumped up just over the last couple of years because of all this extra activity. So I think that there's an almost mandatory infrastructure, rebuild, get efficient. I mean, look at all the equipment that companies are using. It's not efficient. If they replace it, they'll become that much more efficient. And that involves spending money on old economy, you know, machinery and construction and commodities.
18:24And, you know, so I think that this is really an environment where we all poo-poo the idea that the U.S. could ever see a real spending cycle. But we're there. All the ducks are in a row. We're not able to move to other parts of the globe anymore. In fact, we're moving back to the U.S. More activity here, more activity up and down the North America corridor from Canada to Mexico. So I think that all of this is creating this perfect storm for cyclicals to outperform in a really material way over the next several years. Meanwhile, conversations with clients are all about tariffs throwing the world into a global recession.
19:03We're still in this environment where folks are looking at the glass as almost empty. Meanwhile, I feel like it could runneth over. I'm going to use some fancified terms here, too. But I think that we're at a point where the U.S. economy could be really surprisingly strong, which means inflation, which means less Fed cuts. But it's also positive. Coming up, Thanksgiving in the books. But the holiday spirit is just getting started, where consumers are grabbing their gifts as retail posts its best November in years. That is next. And it wasn't just holiday shopping this weekend. Moviegoers piling into theaters and smashing records just how far Moana 2 will go and how wicked is defying gravity.
19:45All that when Fast Money returns back in two. This is Fast Money with Melissa Lee right here on CNBC.
20:02Welcome back to Fast Money. It's Cyber Monday and the holiday shopping season is in full swing. Tim, you can start shopping now. Shop early, Tim. Don't wait till the 24th. I've got a couple things on the books. All right. Retail names have been getting in the spirit. The XRT outperforming the S &P today and over the last month, nearly doubling the benchmark's return since the start of November. And take a look at some of today's big winners. Victoria's Secret, Gap, Lululemon, even Dollar Tree seeing some outsized gains. Can the shopping spree continue through year end? Guy, what do you think? For the stocks, yes.
20:32I mean, for the consumer, we always say never underestimate you as consumers. They will always spend. But now you've got to figure out what's run too much and what is sold off that gives you an opportunity. We actually talked about it when they reported. I thought the Nordstrom's quarter was fine. I thought the guidance was sandbagging. That's what scared people. We thought it could trade lower, probably trade a little lower than I thought. But here we are now back above 23. So a name like Nordstrom's to me, you can make a pretty compelling argument for. Gap might have gotten a little bit ahead of itself here.
21:00Macy's, maybe it has some room, but you're looking for the names that have gotten beaten up, in my opinion, unjustifiably. Yeah, Lulu, Five Below. They've got earnings this week. Yeah, I think you're going to see probably a surprise in the dollar store space, the Five Belows. And they've actually traded okay. Some choppiness, very China-dependent, a lot of tariff headlines. That's determining. Lulu's had a phenomenal run. It's hard for me to hear that Lulu is going to tell you that margins are getting better and that the competitive landscape is getting easier. So I'd be careful on that one. I certainly haven't changed my tune.
21:32Something like a Home Depot. You know, we got an update from both they and Lowe's and their move to all time highs has not been becoming coming from lower interest rates or heat lock loans or dynamics. It's been coming from better margins, even though they've been very cautious on the next couple of quarters. That to me is a setup. I think it goes higher. You know, it's interesting. You know, we talk about e-commerce. We've been talking about it for 25 years, how disruptive it's been. Amazon always runs. I mean, like it always runs into Black Friday, into Cyber Monday. It almost got back up towards those highs.
22:00But another name I think is really interesting is Shopify, which has had tremendous performance this year. It's up 45 percent on the year. They guided up and put up a great quarter just a few weeks ago, huge gap to 52 week highs. And they're talking about GMV, so gross merchandise value, up 22 percent year over year. That's not counting today, Cyber Monday. But that's exactly what it was up last year at this time. So I think that's kind of interesting. Valuation's getting rich. Stock's getting overexposed. If you have any disappointing data over the next week or so, I think some of these stocks could be vulnerable.
22:29All right. There's a lot more Fast Money to come. Here's what's coming up next. It wasn't just turkey leftovers and shopping this Black Friday. Moviegoers following the yellow brick road to a record holiday weekend. The numbers defying gravity. Next. Plus, Fast Money's Obesity Week kicking off with special coverage of the weight loss industry and how leading experts and emerging players are tipping the scales in the space. You're watching Fast Money live from the NASDAQ market site in Times Square. We're back right after this.
23:08Welcome back to Fast Money. The box office is booming this season with Moana 2, Wicked and Gladiator 2 combining for a record holiday weekend, bringing in over$400 million. Julia Warson joins us now to break down the blockbuster numbers. Julia. Well, Melissa, Disney's Moana 2 led a massive box office rebound this weekend with a$221 million domestic box office take, despite lower critics and audience scores than the first movie. Now, Moana 2 had the biggest Thanksgiving opening for a movie ever, the highest ever global weekend for an animated film. And all of this bodes so well for Disney because it has a Lion King prequel, Mufasa, opening on December 20th, and Disney Plus generally gets a boost from sequels driving viewership of an original film.
Read the full transcript
23:54Universal's Wicked and Paramount's Gladiator 2 also continued to perform, driving the five-day box office to a record for Thanksgiving weekend, more than$100 million more than the prior box office record for the weekend. The box office had been down 10.5 % year-to-date through Sunday before Thanksgiving. Now it's down to six and a half percent year to date. Theater stocks all ending the day higher. Cinemark saying it hit a new Thanksgiving record and its second best November domestic box office performance yet. AMC saying that Friday was its highest total revenue Friday of all time. Melissa. Quick question, Julia.
24:34Box office numbers are not inflation adjusted, correct? These are not inflation adjusted. But I think what's really important here is that with those ticket sales also comes things like popcorn sales. And those prices definitely have gone up along with inflation as have ticket sales. So I think even if you account for the fact that there has been ticketing inflation, if you look at the fact that this Thanksgiving box office was$100 million more than the last record, it means that there's definitely has been some growth here and certainly a rebound from those pre-pandemic numbers. I mean, lot of concern that we just not get back to the kind of numbers we saw in 2018-2019.
25:13Julia, thank you. Julie Borsten. I don't think anybody here is trading theater stocks based on this, but a Disney, I believe. We can trade Mufasa, yeah, aka Disney. And I think what we got from that guide, we kind of snickered at a three-year, ultra-detailed guide from the company about three weeks ago. But what you've heard and what's corroborated by what's going on in streaming and profitability there is you're talking about 8 % to 10 % EPS growth over the next couple of years. I think you can buy it. I think you can buy it. I think that streaming business, the momentum is there. And we've forgotten about this flywheel, as we say.
25:47So, Mufasa, let's do it. I like saying that. Mufasa. Go ahead. You're all over it. You just said we're not trading the theater stock. I said I don't think any of you guys would trade the theater stock based on this. I just want to make one quick observation. AMC, if this was like two years ago, would have gone berserk. It was up like 2%. So it says something about like some risk appetite for meme stock. But it's meme time. I mean, if you look at everything else, it would be time. I mean, meme stocks are running. Robinhood's running. Bitcoin's running. Interesting. You look at the analyst calls.
26:21I think Disney reported on the 15th of November, and we talked about it. You get above 124-ish, which was the March high-ish. And now all of a sudden, analysts start to chase. I think the average price target is still in the one teens. You're going to start seeing people raise their price targets to the mid-130s, mid-140s. And that's another name that might have some tailwinds here that nobody's expecting. So I'm sort of with Tim on this one. I think you can own Disney. Favorite holiday movie? Me? Yeah. Die Hard. Die Hard. That's every holiday. It's a movie for all times. No, the memory of Godfather.
26:52I mean, it's, you know, it's in December. Oh, yeah, right? Yeah. This happens all time. I mean, it's over a year, so it's every single season of the year is Godfather. Well, that's right. They're killing Elf right now. Oh, I love Elf. But it's on like 19. A little Christmas and Goodfellas. You guys have to continue. Coming up, sizing up the obesity market, how the GLP-1 drug category could get even fatter in the year ahead. Fast Money's Obesity Week kicks off next with Dr. Scott Gottlieb, the former FDA commissioner here on set with all of the weight loss developments investors should be watching.
27:19More Fast Money right after this. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.
27:37Welcome back to Fast Money. Stocks closing mixed after the Thanksgiving weekend. The S &P 500 and Nasdaq both closing at fresh records. The S &P's 54th record close this year, in fact, but the Dow slightly lowered down nearly 130 points. Shares are blocked getting a boost today, up nearly 5 % after analysts at Bernstein named it their best new idea and upping the price target to 120 from 90. The firm citing significant EBITDA growth into 2025, as well as lower regulatory scrutiny and potential for S &P inclusion at some point. Shares of Apple hitting a fresh record high for a second straight session, now up more than 24 % this year.
28:11And Elon Musk's record Tesla pay package of$5.6 billion rejected again by a Delaware judge. Tesla now ordered to pay$345 million in fees. Well, obesity drug heavyweights Eli Lilly and Novo Nordisk recouping some post-election losses, but still lower than where they were on November 6th, with some lingering uncertainty around how President-elect Trump's picks to lead the federal health agencies would impact the GLP-1 category. For more on the key developments in the space to watch, we're joined by former FDA Commissioner Dr. Scott Gottlieb. He's a CNBC contributor, serves on the board of Pfizer as well.
28:45Dr. Gottlieb, great to see you here in person. Welcome to Fast Money. Thanks a lot. The last time I specifically talked to you about weight loss drugs was a while ago, maybe a year ago even. And so I'm wondering what you think of the ramp. The last time we chatted, you said that it was a promising space akin to statins. But now we're seeing some, I don't want to say evidence, but maybe some data points, some concerns of the growth trajectory isn't there. The demand isn't keeping up. What's your take? Yeah, look, I think if you look back to when we spoke probably more than a year ago, I would have had an expectation that they would have grown more quickly.
29:19But I think as new indications come on these labels, certainly the indication around cardiovascular risk was a real inflection point. I think in the coming year, you're going to see new indications get on these labels, maybe for sleep apnea, musculoskeletal diseases. And there's also going to be a big data card that gets turned over by Novo Nordisk around reduction of signs and symptoms of dementia. And if that's positive and there's some indication from smaller trials that that could be a positive study, I think that's going to be another big inflection point. And so I think the future looks very promising for these drugs from a public health standpoint.
29:51How do you see anything changing in terms of your expected trajectory, just absent political wins, and when the new administration comes and whether or not anything will change, just because we know Robert F. Kennedy Jr. is more sort of, he endorses more nutrition and is in favor of those sorts of interventions as opposed to medications. Look, I don't think the public health need is going to change. We've seen some comments generally around excess utilization, so marginal utilization, and maybe too much utilization among children. I think when you look at the actual data, the average BMI of patients who are on Lilly's drug is around 37.
30:27The average BMI of people who are on Wigovia, which is Novo Nordisk's drug, is 38. That's quite high. That's about 290 pounds and a 6-foot male. So that's class 2 obesity. So that's not marginal utilization. That's people who are properly indicated for this drug. And when you look at the pediatric scripts, which has also come under some scrutiny, not a lot of children are on these drugs right now. It's growing quickly. But when you look at the actual prescriptions, there's about 4 ,000 children on Wagovi, according to 2023 data. And if you look at Lilly's data, it's less than 1 % of their total user base are children.
31:00And, you know, these are children who are very obese, probably have or are on the pathway towards developing diabetes. that's a very high value use of these drugs from a public health standpoint. If you can get a child on these drugs who have a very high BMI and get them to lose weight on these medications. So I think that when you look inside the data on who's using it, you're going to see also appropriate utilization. Change gears. It's great to have you on. What is it, Dr. Oz, for Center for Medicaid and Medicare mean to you? Yeah, look, I'm very bullish on Oz. I think that he's going to be a good leader of that organization.
31:32He's assembling a very good team right now. I think they're going to start announcing people that they're going to be putting in place in that organization. I think he's been very savvy about who he's talking to, about filling key roles there. But, look, I worked at Medicare. You know, you spend your days in the administrator's office worrying about and thinking about how to do conversions and injectables from infused drugs to, you know, injectable drugs. It's mind-numbing work, the things that come up to that front office. I think Oz is probably going to be more of an outside player. If you think about today's senior citizens, they all grew up watching him.
32:03I think he can lead a real revolution or renaissance in trying to get people into fitness programs, trying to get people more aware of their health than the senior population, and leave some of the day-to-day operation to people who are more technical. So I think he'll be a different kind of leader, and I think he could be really impactful in that organization. Back to the weight loss space, you mentioned other indications. What do you think will move the needle in terms of opening up the addressable market, or do you see it sort of as people who are on injectables switching to an oral, so therefore you're not really gaining in market share.
32:35Yeah, look, you have data on Orpheglerpron, which is Lilly's oral drug coming next year. You're probably going to see Novo potentially moved for the higher dose version of Rebelsis to get that into the market for the weight loss indication. The data looked good there. I think they're supply constrained, and that's why they haven't moved that forward. And you're also going to have data next year on the two follow-on products to ZepBound, which is Lilly's drug, and Wigovie, which is Novo's drug, kangrasemir and retrotutide, excuse me, it's a hard name. So I think as new drugs come into the market, it's going to expand the market and some of these drugs could be more effective for certain patients.
33:08But I think it's going to just be the continued clinical data that shows all the downstream health benefits of getting people who are indicated, properly indicated for these drugs based on BMI onto these medications, helping them lose weight. The cardiovascular risk reduction from the SELECT trial, 20 % reduction in high-risk patients in MACE events, which is stroke and heart attack. That's quite profound, and that was on top of patients who were already maximized on available therapy. So to be able to introduce a new drug and achieve a 20 % reduction in risk of heart attack and stroke is really profound from a medical standpoint.
33:40Why do you think the FDA has vacillated on terzepatide in the shortage list, taking off the shortage list, saying, oh, no, no, you have some more time here before we reconsider this? Yeah, I'm not sure. I don't think that was a political decision. That was my first assumption that this was a political decision ahead of the election. From what I've heard, I don't think that was the case. I think it's truly undergoing some more scrutiny. But I would expect the FDA to move on that before the end of the term, because if they leave this on the shortage list or they take it off the shortage list and allow the compounders to continue on the market, they're really going to undermine their authorities on compounded drugs.
34:12I don't think they want to leave that precedent in place. So this is something I think they may try to move on to close this out and try to move the compounders, at least for the Lilly drug, where the drug isn't on the shortage list off the market. Right. Dr. Gottlieb, great to see you. Thanks for coming by. Dr. Scott Gottlieb. And be sure to keep tuning in all week for Fast Money's continuing obesity week coverage. We'll be joined by CEOs of Altimmune, Structure Therapeutics, BioAge, and more. That's every day right here, 5 p.m. Eastern time on CNBC. What's the trade here, Dan? Well, I think you have to look at what the Biden administration just proposed, right?
34:44So if you had Medicare coverage, you had expansion to Medicaid, what does that mean for pricing? I I think they indicated maybe there's 8 million potential patients in those two groups. And if one of the issues about supply and demand, if the supply is coming more in line, if there's going to be more companies offering this sort of stuff and then the price comes down, I mean, this could be something that really continues the tale of this. And I think that I think Lilly and Novo have kind of been de-risked a little bit, taking a lot of that enthusiasm out of the stocks from the highest recent highs.
35:12Yeah. What do you how do you feel about health care and pharma? I think so. We're underweight health care. And, you know, I think this is a sector that is very crowded, especially the GLP-1 theme. And I think, you know, the question is how much good news is not in the stocks already. And I feel like it's hard to, you know, really see these as a continued outperformer. No question about the addressable markets. That's been an interesting part of this conversation with Dr. Gottlieb. I think the Amgen reaction on their phase, too, you know, ultimately that that Maritime data, I think, is being underestimated for what especially the second half of that data relief.
35:47I think Amgen is interesting. Coming up, changes in the driver's seat at Stellantis. The automaker seat is stepping down amid falling sales with a C-suite shuffle. Help the stock make a U-turn. Plus, new terrorist threats from President-elect Trump and why some Chinese tech execs are running into visa problems ahead of next year's CES Consumer Electronics Show. The details when Fast Money returns.
36:13Welcome back to Fast Money. French-Italian automaker Stellantis dropping more than 6 % today. The company announcing CEO Carlos Tavares is stepping down effective immediately and that the process to appoint his replacement is well underway. This comes as Stellantis struggles with falling sales, a company issuing profit warnings in late September, setting broader industry challenges, difficulties in the world's largest auto market, China. shares of Stellantis down 47 % this year. And it just dropped, and it wasn't good news necessarily. It was sort of like Intel. Maybe they had bigger problems.
36:43Yeah, so, okay, our correct staff back in EC. Pull up a chart from October of 2022, and you'll see where we traded down today is where we traded down about two or so years ago. We did it on big volume today, probably three times normal volume, which means, in my opinion, given this dramatic drop over the last year, basically, today might have been capitulation day. So if you're looking to trade a stock around a level, I think this one will get you done. All right. Coming up, President-elect Donald Trump turning up the tariff heat, why he could be going after some countries with 100 percent tariffs and the potential fallout.
37:13That's next. More Fast Money in 2.
37:21Welcome back to Fast Money. President-elect Donald Trump taking aim at the BRIC countries in his latest round of tariff threats, saying the group will face levies of 100 percent if they move away from the U.S. dollar as a reserve currency. Our Eamon Javres is in Washington with the very latest. Eamon. Hey there, Melissa. That's right. Former President Trump's threat to impose 100 percent tariffs on the BRICS if they try to undermine the U.S. dollar's status as a reserve currency. It comes at a time of increased trade and financial cooperation between Russia and China as those two countries try to offer an alternative to the U.S.-led global order.
37:55In a social media post, the former president wrote this, we require a commitment from these countries that they will neither create a new BRICS currency nor back any other currency to replace the mighty U.S. dollar, or they will face 100 % tariffs and should expect to say goodbye to selling into the wonderful U.S. economy. Now that threat comes on top of Trump's threat last week for an additional 10 % tariff on goods from China unless China cracks down on the illegal fentanyl trade. One big unknown here, Melissa, is just how sustainable a 100 % tariff on Chinese goods would be. It could cause prices to spike inside the United States on a vast array of products, resulting in a political blowback for the political party that supported it.
38:40And of course, the other thing, Melissa, here is that the dollar became the global reserve currency because of its value to the users of it, not because the United States sort of badgered them into using it. And so for users around the world who look at the dollar, they'll say, you know, we're either going to do this or we're not if it makes sense for us, you would imagine. Right. Eamon, thank you. Eamon Javers in D.C. Meanwhile, CES, the world's largest tech showcase, comes to Las Vegas next month. And more than 30 percent of this year's 4 ,000 plus registered exhibitors are from China. But many of their employees say they're being denied entry visas for the event, even as the Trump administration gears up to impose additional 10 percent tariffs on all Chinese goods.
39:19Our Eunice Yoon joins us here on set with the details. And, Eunice, you know, I read the story and I thought, wow, this really underscores how bad things are getting when it comes to the U.S. versus China in tech. Yeah, but it's not particularly surprising because we have seen that visas are being denied by academics and for students. And so that's been a big complaint that we've heard. But from the State Department's perspective, they told me just earlier today that they are not allowed to discuss any individual cases because of U.S. law. But the state media is calling on the U.S. to resolve the issue and saying that this is a protectionist move.
39:53Overall, though, to your point, this is really emblematic of some of the problems that we are seeing and the step-for-tat and step-by-step action that we're expected to see, especially as you go into a Trump administration. When it comes to the U.S. moves to block crucial parts, crucial chips to the AI industry in China, an industry that China desperately wants to grow at a time when China is basically on its knees when it comes to the economy. I mean, how is that being perceived domestically there? And do you think that China is in a different position than during the front first Trump administration because of where the economy is?
40:29Yeah, I think this that's really it's really, really different just from a reporting standpoint, because it's just such a tight environment now. Now, you're seeing that President Xi Jinping's agenda is much clearer. You were talking a little bit about tech. It's really important. I think that it's more important than growth and something that a lot of investors might assume is less important than growth. But growth is actually something that's kind of fallen by the wayside. And the tech dominance and the national security part is much, much more important. Obviously great to have you here, number one.
41:02Number two, I think the yuan is at like a four-month low. And J.P. Morgan just put a note out. They could see China allowing the yuan to depreciate by about 15 percent in response to these tariffs. Thoughts on that? Yeah, there's a lot of people who say the same thing, just that that's one way that we had seen the Chinese react in the first administration under President Trump. But that this is something that we could see again. But I think what's going to be different this time is that there's a willingness now that we've seen on the part of the Chinese to actually retaliate directly against U.S.
41:33companies. Because we have seen that with PVH, the owner of Calvin Klein, also with Intel. And I think that the Chinese have, over the past couple of years, been weaning themselves off of being so reliant on the U.S. And that's one portion. But also that there isn't necessarily, they have their agenda. And if the U.S. comes along or not, they don't really care that much. I think that they're just going to go ahead with what they need, which usually involves tech dominance. So, Eunice, and yeah, it's great to have you. And so China playing the long game. And we've often talked about Apple being at risk and at times.
42:10And so there's, you know, I think the Journal has an article. There's a highlight on BYD doing a lot of the manufacturing for them on a local level that they essentially have two primary Chinese manufacturers. Are you worried about this? Should Apple investors think that the long game is now 10 years into this and at some point Apple is going to get tapped on the wrist? I think that at some point when Apple doesn't become isn't as useful to the Chinese government in that the overarching agenda for technology dominance, then Apple will fall by the wayside. I mean, it's just going to be used until it's no longer necessary.
42:46Eunice is here all week. Come on. So we'll have a back. Thank you. Next final trades. Thank you.
43:21specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.
From the publisher
Intel CEO Pat Gelsinger stepping down, as the chipmaker looks to bounce back from a tumultuous couple of years. What the turnaround plans may look like now, and how Intel can keep up with competition. Plus Fast Money’s Obesity Week kicks off. The emerging players in the weight-loss drug battle, and what industry leaders see next for the space.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
